Explore Treatments for Myasthenia Gravis (MG)

Myasthenia Gravis (MG) is a long-term autoimmune condition that causes weakness in the body’s voluntary (skeletal) muscles—those used for movement, speaking, chewing, and breathing. Muscle weakness often worsens with activity and improves with rest. MG occurs when the immune system disrupts the normal communication between nerves and muscles by blocking or destroying acetylcholine receptors, which are essential for muscle contraction. Without this signal, muscles can’t respond properly, leading to weakness. The exact cause of MG is not fully understood. In some cases, a tumor or abnormality in the thymus gland may play a role in triggering the condition. Genetics and other unknown factors may also increase a person’s risk of developing MG. While there is currently no cure, effective treatments can significantly improve symptoms and muscle strength. Some people experience temporary remission, during which symptoms disappear, and medications may not be needed. MG can affect people of any age, but it is most commonly diagnosed in, women under the age 40 and men over the age 60.

Treatments Offered by CSI

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma is rigorously processed and purified to ensure product safety and integrity. Intravenous immunoglobulin (IVIG) contains antibodies that provide broad protection against a wide range of bacteria and viruses. It is administered intravenously and is primarily used to treat three categories of conditions: primary immunodeficiency diseases, autoimmune disorders, and certain neurological conditions. 

  • Alyglo 10% 
  • Asceniv 10% 
  • Bivigam 10% 
  • Gammagard S/D 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Gammaplex 5% 
  • Gammaplex 10% 
  • Octagam 5% 
  • Octagam 10% 
  • Panzyga 10% 
  • Privigen 10% 
  • Yimmugo 10% 

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma undergoes rigorous processing and purification to ensure the highest standards of safety and product integrity. Subcutaneous immunoglobulin (SCIG) contains antibodies that offer broad protection against a wide range of bacteria and viruses. It is administered under the skin (subcutaneously) and is primarily used to treat primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy (CIDP). SCIG is also being studied in clinical trials for use in additional conditions. 

  • Cutaquig 16.5%  
  • Cuvitru 20% 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Hizentra 20% 
  • HyQvia 10% (facilitated SCIG)  
  • Xembify 20%